We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Changes in Liver Function After Stereotactic Body Radiation Therapy Measured by PET/CT

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01213758
First Posted: October 4, 2010
Last Update Posted: October 30, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Danish Cancer Society
Information provided by (Responsible Party):
University of Aarhus
October 1, 2010
October 4, 2010
October 30, 2017
June 2010
April 2016   (Final data collection date for primary outcome measure)
Uptake of FDGal [ Time Frame: Before, 1 month and 3 months after stereotactic radiotherapy ]
Volumetric uptake of FDGal can be measured is measured by PET/CT
Same as current
Complete list of historical versions of study NCT01213758 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Changes in Liver Function After Stereotactic Body Radiation Therapy Measured by PET/CT
Radiation Induced Change of Liver Function Measured by Uptake of the Galactose Analogue FDGal and PET/CT
Patients treated with stereotactic radiotherapy for liver tumors undergo PET/CT using the galactose analogue 18-F-deoxy-galactose (FDGal) before and after radiotherapy. This technique provides volumetric mapping of liver function and it allows quantisation of liver function. The method may be used for selection of patients for stereotactic radiotherapy of liver tumors, for determination of radiation induced liver dysfunction and may be included into the treatment planning process of stereotactic radiotherapy.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample
Patients with liver tumors reffered for stereotactic body radiation therapy
  • Hepatocellular Carcinoma
  • Cholangiocarcinoma
  • Metastases
  • Stereotactic Body Radiotherapy
Other: Measuring liver function by PET/CT
Measuring liver function by use of FDGal and PET/CT before, 1 month and 3 months after stereotactic radiotherapy for liver tumors
Liver tumors
Patients where stereotactic body radiation therapy is planned for primary or metastatic liver tumors.
Intervention: Other: Measuring liver function by PET/CT
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
14
April 2016
April 2016   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • liver tumor
  • referred for stereotactic radiation therapy
  • age > 18 years

Exclusion Criteria:

  • Impaired kidney function
  • Pregnancy
Sexes Eligible for Study: All
18 Years to 85 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Denmark
 
 
NCT01213758
AarhusLiverRadGal
No
Not Provided
Not Provided
University of Aarhus
University of Aarhus
Danish Cancer Society
Principal Investigator: Morten Høyer, MD PhD Aarhus University Hospital
University of Aarhus
October 2017